New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
10:19 EDTNYMXNymox reports new safety data for Phase 3 BPH drug
Nymox Pharmaceutical announced new clinical data supporting the positive safety profile of NX-1207, the company's lead compound in late Phase 3 testing for prostate enlargement, or benign prostate hyperplasia, BPH. "Recent pharmacokinetic studies using a newly developed highly sensitive blood test for NX-1207 have shown that the drug is undetectable in the blood post-injection, providing strong evidence that the drug, once injected into the prostate, remains confined to the prostate and thus unable to affect other organs such as the liver, kidneys, heart, or testes" the company said. These results are consistent with the pharmacological profile of the drug and with the extensive body of safety data from the more than 1,000 men treated with the drug to date demonstrating the absence of any significant drug-related side effects. In addition, men treated with NX-1207 have not displayed any signs of an allergic or other immune reaction to the drug either on first injection or repeat injection. Extensive clinical immunogenicity testing of men in the company's pivotal Phase 3 trials and Phase 3 repeat injection safety studies have found no evidence of anti-drug antibody formation after exposure to the drug. The company will present more detailed scientific data from these studies at upcoming medical conferences, it said.
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
10:03 EDTNYMXNymox says Phase 2 NX03-0040 study successfully met pre-determined endpoints
Nymox Pharmaceutical Corporation announced results from the completion of the company's U.S. 40 month localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate. The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.The clinical trial commenced in February 2012 at 28 U.S. investigational clinical trial sites and enrolled 147 patients with low grade localized prostate cancer. The study lasted 40 months overall from the first patient randomized to the last patient 18 month endpoints. "These results demonstrate that a single targeted office injection of fexapotide has led to statistically significant improvement in outcomes with much less surgery or radiotherapy required after 18 months. This means a reduction in patient discomfort, and a reduction in permanent side effects and life changes when the more invasive treatments are required," said Paul Averback, CEO of Nymox.
February 4, 2016
11:19 EDTNYMXNymox announces private placement equity investment of $2.1M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use